Top Markets
Coin of the day
Ember Therapeutics, Inc. Ember Therapeutics, Inc.

Ember Therapeutics, Inc.

EMBT
Rangering i aksjer #42686
Ember Therapeutics, Inc. operates as a biopharmaceutical company currently in... Ember Therapeutics, Inc. operates as a biopharmaceutical company currently in its clinical development phase. Its core mission involves exploring the therapeutic applications of bone morphogenetic protein-7 (BMP-7) to engineer regenerative treatments. These innovative therapies are designed to alter the course of osteoarthritis, reverse insulin resistance, and inhibit or undo organ fibrosis in diseases such as chronic kidney disease and Alport's syndrome, alongside metabolic conditions like obesity and type 2 diabetes. Among its leading BMP-7-based drug candidates, MT-006 has successfully completed a Phase 2a clinical trial focused on osteoarthritis. Furthermore, MT-007, aimed at CKD and Alport syndrome; MT-008, specifically for Alport syndrome; and MT-009, targeting metabolic disease, have all concluded their preclinical trial phases. The company also maintains a substantial intellectual property portfolio, encompassing approximately 450 patents related to BMP-7, its associated protein families, various derivatives, novel delivery systems, specialized formulations, supporting clinical data, and materials produced under current good manufacturing practices. Ember Therapeutics, Inc. was established in 2010 and is headquartered in New York, New York.
Aksjekurs
$0.0001
Sist synkronisert: 2026-02-06
Markedsverdi
$398.00
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Ember Therapeutics, Inc. (EMBT)

Kategori

P/S-forhold for Ember Therapeutics, Inc. (EMBT)
P/S-forhold per 2026 TTM: 0
Ifølge Ember Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Ember Therapeutics, Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
9.88 -
US
10.30 -
NL
- -
CH
4.98 -
BE
- -
KR